Marshall Wace’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Marshall Wace’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Buy	342,265 +161,965	+90%	+$497K	﹤0.01%	2114
2025 Q4	$642K	Buy	180,300 +155,136	+616%	+$575K	﹤0.01%	2140
2025 Q3	$87.8K	Sell	25,164 -1,451,782	-98%	-$4.97M	﹤0.01%	2672
2025 Q2	$3.03M	Buy	+1,476,946	New	+$3.69M	﹤0.01%	1373
2024 Q1	–	Sell	-39,282	Closed	-$80.1K	–	2803
2023 Q4	$80.1K	Buy	+39,282	New	+$68.1K	﹤0.01%	2057
2021 Q4	–	Sell	-252,439	Closed	-$2.5M	–	4280
2021 Q3	$2.5M	Buy	252,439 +1,400	+0.6%	+$13.9K	0.01%	1388
2021 Q2	$2.5M	Hold	251,039	–	–	0.01%	1269
2021 Q1	$2.5M	Buy	251,039 +1,071	+0.4%	+$11.4K	0.01%	1203
2020 Q4	$2.7M	Hold	249,968	–	–	0.01%	818
2020 Q3	$2.59M	Buy	+249,968	New	+$2.6M	0.02%	738

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's STLN Position: Q1 2026 in Review

Marshall Wace increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 90% in Q1 2026, buying an estimated $497K and bringing the position to 342,265 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2114.

Marshall Wace first reported a position in STLN in Q3 2020 and has held it in 10 quarters since. The position peaked at $3.03M in Q2 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Marshall Wace held 342,265 shares of Starling Oncology Institute, Inc. Common Stock worth $1.05M as of Q1 2026.
Marshall Wace bought 161,965 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $497K.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2114 holding.
Marshall Wace first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2020 and has held it in 10 quarters since.
Marshall Wace's Starling Oncology Institute, Inc. Common Stock position peaked at $3.03M in Q2 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.